Introduction {#Sec1}
============

Mutations in the *SCN5a* gene encoding the α-subunit of the cardiac voltage-gated Na^+^ channel are well established to underlie hereditary arrhythmic syndromes which may result in sudden cardiac death. On the one hand, *gain-of-function* mutations which increase inward depolarising currents and consequently prolong the ventricular action potential are associated with arrhythmogenicity in the congenital long QT syndrome type 3 (LQT3) \[[@CR23]\]. On the other hand, *loss-of-function* mutations which decrease such currents are associated with arrhythmogenicity in the Brugada syndrome (BrS) \[[@CR1]\]. In this case, spatial heterogeneities in the degree of shortening of the ventricular action potential result in characteristic electrocardiographic changes, namely a partial right bundle branch block pattern with ST segment elevation in the right precordial leads \[[@CR2]\].

Despite the similar clinical outcomes of LQT3 and BrS, class 1A and 1C, anti-arrhythmic agents, exemplified by quinidine and flecainide respectively, exert contrasting effects on arrhythmogenicity in these two syndromes \[[@CR31]\]. Thus in LQT3, quinidine is pro-arrhythmic \[[@CR33]\] and flecainide is anti-arrhythmic \[[@CR22]\]. In contrast, in BrS quinidine is anti-arrhythmic \[[@CR24]\], while flecainide is pro-arrhythmic \[[@CR7]\] and used to unmask the arrhythmic phenotype in asymptomatic patients. These contrasts are precisely reflected in results from our murine models of LQT3 \[[@CR39]\] and BrS \[[@CR38]\], emphasizing the translatability of results obtained from such systems. Furthermore, both quinidine and flecainide are known to have the potential for pro-arrhythmic effects \[[@CR12], [@CR30]\].

These similarities and differences have parallels in the physiological changes thought to underlie arrhythmogenicity in LQT3 and BrS. Thus circus-type re-entry \[[@CR2]\], requiring both an initiating trigger and a re-entrant substrate, has been implicated in arrhythmogenicity in both these conditions. Of these requirements, both conditions are associated with triggering extrasystoles \[[@CR3]\]. In LQT3, these are initiated by early after-depolarizations attributable to action potential prolongation \[[@CR42]\], while in BrS they are initiated by phase 2 re-entry \[[@CR20], [@CR46]\]. Furthermore, in both LQT3 and BrS, arrhythmia occurs against a re-entrant substrate \[[@CR3]\]. In LQT3 this is provided by increased transmural dispersion of repolarization \[[@CR13], [@CR27], [@CR42]\]. While increased transmural dispersion of repolarization has also been demonstrated in some studies on BrS \[[@CR3]\], increased epicardial dispersion of repolarization \[[@CR2]\] and slowed conduction \[[@CR29]\] are also implicated. Thus studies in murine hearts have associated alterations in transmural dispersion of repolarization, reflected in relationships between epicardial and endocardial action potential durations, with arrhythmogenicity in models of LQT3 but failed to do so in models of BrS \[[@CR21], [@CR33], [@CR38], [@CR39], [@CR42]\].

Arrhythmogenicity has often been associated with increases in the slopes of restitution curves, plotting action potential duration against the preceding diastolic interval, to greater than unity \[[@CR14], [@CR17]--[@CR19], [@CR28], [@CR40]\]. Possible mechanisms that might underlie this association have been discussed in detail on a number of occasions \[[@CR11], [@CR25], [@CR43], [@CR44]\]. Furthermore, decreases in the slopes of such curves are associated with the anti-arrhythmic effects of several clinically important agents including amiodarone, bretylium and procainamide \[[@CR11], [@CR26], [@CR32]\]. Such associations have previously been demonstrated in a pharmacological model of LQT2 \[[@CR45]\] but has not been assessed in LQT3 or in BrS.

The present study compares an analysis examining transmural dispersion of repolarization, assessed by comparing epicardial and endocardial action potential durations obtained over a range of heart rates and previously established to predict arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts \[[@CR34]\], with another examining effects on restitution curve parameters. This represents the first occasion on which restitution curves have been constructed in a murine system, in relation to BrS or LQT3, or indeed in any genetic model of an hereditary arrhythmic syndrome. To this end, the monophasic action potential (MAP) technique and an established Langendorff-perfused system \[[@CR15], [@CR34]--[@CR36]\] are used to study genetically modified mice modelling LQT3 (*Scn5a+/Δ*) \[[@CR13]\] and BrS (*Scn5a+/−*) \[[@CR29]\] before and after exposure to quinidine and flecainide. We proceed to demonstrate that while the former criterion fails, the latter produces predictions in full agreement with the arrhythmogenic findings in every case and thus suggest that alterations in the slopes of restitution curves are associated with arrhythmogenicity in both LQT3 and BrS.

Materials and methods {#Sec2}
=====================

Experimental animals {#Sec3}
--------------------

Wild-type (WT), *Scn5a+/Δ* and *Scn5a+/−* 129 Sv mice aged 3--6 months were housed at 21 ± 1°C with 12 h light/dark cycles. They were fed sterile chow (RM3 Maintenance Diet, SDS, Witham, Essex, UK) and had free access to water. All procedures complied with the UK Animals (Scientific Procedures) Act 1986.

Solutions {#Sec4}
---------

Solutions were based on bicarbonate-buffered Krebs-Henseleit solution (119 mM NaCl, 25 mM NaHCO~3~, 4 mM KCl, 1.2 mM KH~2~PO~4~, 1 mM MgCl~2~, 1.8 mM CaCl~2~, 10 mM glucose and 2 mM Na-pyruvate; pH adjusted to 7.4) and were bubbled with 95% O~2~/5% CO~2~ (British Oxygen Company, Manchester, U.K). Drug-containing solutions were prepared by adding flecainide (Sigma-Aldrich, Poole, UK) to final concentration of 1 μM and quinidine (Sigma-Aldrich, Poole, UK) to final concentrations of 1 and 10 μM: these concentrations were chosen to reflect clinically therapeutic values (effective free and total plasma concentrations of 0.79 and 1.48 μM, respectively, for flecainide and 0.74 and 7.9 μM, respectively, for quinidine) \[[@CR9]\].

Preparation {#Sec5}
-----------

A Langendorff-perfusion protocol previously adapted for murine hearts \[[@CR4]\] was used. Briefly, mice were killed by cervical dislocation \[Schedule 1: UK Animals (Scientific Procedures) Act 1986\] before hearts were quickly excised and placed in ice-cold bicarbonate-buffered Krebs-Henseleit solution. Short sections of aorta were cannulated under the surface of the solution and attached to a custom-made 21-gauge cannula filled using an aneurysm clip (Harvard Apparatus, Edenbridge, Kent, UK), within 90 s of excision. Fresh Krebs-Henseleit solution was passed through 200- and 5-μm filters (Millipore, Watford, UK) and warmed to 37°C using a water jacket and circulator (Techne model C-85A, Cambridge, UK). This solution was then used for constant-flow retrograde perfusion, thereby circumventing any changes in coronary vascular resistance and therefore flow that might otherwise result from the effects of the drugs studied \[[@CR10]\], at 2--2.5 ml/min, driven by a peristaltic pump (Watson-Marlow Bredel model 505S, Falmouth, Cornwall, UK). Hearts were regarded as suitable for experimentation if they regained a healthy pink colour and began to contract spontaneously on re-warming.

Electrophysiological measurements {#Sec6}
---------------------------------

An epicardial MAP electrode (Hugo Sachs, Harvard Apparatus, UK) was placed against the basal left ventricular epicardium. A custom-made endocardial MAP electrode consisting of two twisted strands of high-purity Teflon-coated silver wire of 0.25 mm diameter (Advent Research Materials, UK) was manufactured. A small access window was created in the interventricular septum to allow access to the left ventricular endocardium \[[@CR8]\]. The Teflon coating was removed from the distal 1 mm of the electrode; this was then galvanically chlorided to eliminate DC offset, inserted and placed against the septal endocardial surface. MAPs were amplified, band-pass filtered (0.5 Hz to 1 kHz: Gould 2400S, Gould-Nicolet Technologies, Ilford, Essex, UK) and digitised at a sampling frequency of 5 kHz (micro1401, Cambridge Electronic Design, Cambridge, UK). Analysis of MAPs was performed using Spike II (Cambridge Electronic Design, Cambridge, UK).

Experimental protocol {#Sec7}
---------------------

A bipolar platinum stimulating electrode (1 mm inter-pole spacing) was placed on the basal surface of the right ventricular epicardium. Square-wave stimuli (Grass S48 stimulator, Grass-Telefactor, Slough, UK) of 2 ms duration and amplitudes of twice the excitation threshold were initially applied to hearts at a constant baseline cycle length (BCL) of 125 ms until MAPs showed stable baselines, rapid upstroke phases that reached consistent amplitudes and smooth repolarization phases \[[@CR16]\] and for at least 10 min. Before subsequent recordings were made, hearts were then exposed to test solutions for 20 min while stimulation was continued.

In initial experiments, MAPs were recorded during regular stimulation at a BCL of 125 ms. Arrhythmogenicity was then assessed both during regular stimulation and using an *extrasystolic stimulation protocol* \[[@CR37]\] previously adapted for the study of arrhythmogenesis in murine hearts incorporating the *Scn5a+/Δ* and *Scn5a+/−* mutations \[[@CR13], [@CR38]\] and described below. Hearts were then subjected to an adapted *dynamic pacing protocol* \[[@CR17]\] explained in detail below, and the data obtained used to construct restitution curves.

Data analysis {#Sec8}
-------------

All data are presented as means ± standard errors of the means and include the number of hearts studied. Comparisons between data sets used analysis of variance (significance threshold set at *P* ≤ 0.05). Curve fitting of particular functions to data sets used a Levenberg-Marquardt algorithm (OriginPro 7.5, OriginLab, MA, USA).

Results {#Sec9}
=======

The experiments made direct measurements of MAPs from intact Langendorff-perfused murine hearts. They compared the extents to which relationships between epicardial and endocardial action potential durations and the slopes of restitution curves are associated with arrhythmogenicity in genetic models of the congenital LQT3 (*Scn5a+/Δ*) and of the BrS (*Scn5a+/−*), and in wild-type (WT) controls. They began by successfully demonstrating that these experimental models recapitulated arrhythmic phenotypes observed clinically as well as confirming the anticipated effects of treatment with clinically-relevant \[[@CR6]\] concentrations of flecainide (1 μM) and quinidine (1 or 10 μM). Hearts were exposed to solutions for 20 min while stimulated at a constant BCL of 125 ms before recording was commenced.

Arrhythmogenicity in WT, *Scn5a+/Δ* and *Scn5a+/−* hearts subject to both regular and extrasystolic stimulation recapitulates clinical observations {#Sec10}
---------------------------------------------------------------------------------------------------------------------------------------------------

Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} show results obtained from WT (Figs. [1](#Fig1){ref-type="fig"}a, [2](#Fig2){ref-type="fig"}a), *Scn5a+/Δ* (Figs. [1](#Fig1){ref-type="fig"}b, [2](#Fig2){ref-type="fig"}b) and *Scn5a+/−* (Figs. [1](#Fig1){ref-type="fig"}c, [2](#Fig2){ref-type="fig"}c) hearts treated with control solution (A) and with solutions containing 1 μM flecainide (B), 1 μM quinidine (C) and 10 μM quinidine (D). Figure [1](#Fig1){ref-type="fig"} illustrates MAP waveforms recorded from the epicardia of hearts during the extrasystolic stimulation procedure showing arrhythmic waveforms in situations where arrhythmic activity was observed in \>50% of cases; Fig. [2](#Fig2){ref-type="fig"} quantifies the incidence of such arrhythmic activity both during regular stimulation (i) and during the extrasystolic stimulation procedure (ii). Fig. 1Arrhythmic activity resulting from extrasystolic stimulation. Epicardial monophasic action potential (MAP) recordings illustrating the result of the application of extrasystolic stimuli to WT (**a**), *Scn5a+/Δ* (**b**) and *Scn5a+/−* (**c**) hearts treated with control solution (*A*) and with solutions containing 1 μM flecainide (*B*), 1 μM quinidine (*C*) and 10 μM quinidine (*D*). Traces show arrhythmic activity where this was observed in ≥50% of casesFig. 2Incidences of arrhythmic activity in WT, *Scn5a+/Δ* and *Scn5a+/−* hearts subjected to the extrasystolic stimulation procedure. Percentage of WT (**a**), *Scn5a+/Δ* (**b**) and *Scn5a+/−* (**c**) hearts demonstrating arrhythmic activity during regular stimulation (i) and during the extrasystolic stimulation procedure (ii). In both these cases, MAPs were obtained during treatment with control solution (*A*) and with solutions containing 1 μM flecainide (*B*), 1 μM quinidine (*C*) and 10 μM quinidine (*D*). *Hashing* indicates hearts demonstrating arrhythmic activity, and *dots* indicate hearts not demonstrating such activity

The frequencies of arrhythmic phenomena in hearts subjected to regular stimulation at a BCL of 125 ms were relatively low irrespective of the genetic or pharmacological conditions but were nevertheless consistent with clinical expectations. First, zero out of seven WT hearts (\~0%, Fig. [2](#Fig2){ref-type="fig"}a, i) exposed to control solution (A) demonstrated arrhythmic activity, while treatment with flecainide (B) led to arrhythmic activity in only one out of six (\~17%) cases. Furthermore, such hearts never showed arrhythmic activity during treatment with 1 μM quinidine (C, zero out of six hearts, \~0%) and again did so in only one out of six cases (\~17%) with 10 μM quinidine (D). Secondly, arrhythmic activity did occur in one out of six (\~17%) *Scn5a+/Δ* hearts (Fig. [2](#Fig2){ref-type="fig"}b) treated with control solution (A) and was absent in all cases (zero out of six hearts, \~0%) during treatment with flecainide (B). Arrhythmic activity was not observed (zero out of four hearts, \~0%) during treatment with 1 μM quinidine (C) but did occur in one out of five hearts (\~20%) exposed to 10 μM quinidine (D). Thirdly, two out of nine *Scn5a+/−* hearts (\~22%, Fig. [2](#Fig2){ref-type="fig"}c) exhibited arrhythmic activity during exposure to control solution (A). Such arrhythmic activity was also observed in one out of five hearts (\~20%) treated with flecainide (B). Arrhythmic activity was then absent after treatment with either 1 μM (C) or 10 μM (D) quinidine (zero out of five, 0%, and zero out of six, 0%, hearts, respectively).

In contrast, extrasystolic stimulation (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, ii) revealed clearer trends in arrhythmogenicity in full agreement with clinical expectations. First, while zero out of seven WT hearts (0%, Fig. [2](#Fig2){ref-type="fig"}a, ii) exposed to control solution (A) exhibited arrhythmic activity, treatment with flecainide (B) increased the incidence of such events to two out of six hearts (\~33%). Furthermore, exposure to 1 μM quinidine (C) resulted in arrhythmic activity in four out of eight hearts (\~50%), while exposure to 10 μM quinidine (D) resulted in arrhythmic activity in three out of six hearts (\~50%). Secondly, one out of five *Scn5a+/Δ* hearts (\~20%, Fig. [2](#Fig2){ref-type="fig"}b, ii) demonstrated arrhythmic activity during exposure to either control solution (A) or flecainide (B). However, exposure to quinidine resulted in arrhythmic activity in three out of five hearts (\~60%) at 1 μM (C) and four out of four hearts (\~100%) at 10 μM (D). Thirdly, *Scn5a+/−* hearts (Fig. [2](#Fig2){ref-type="fig"}c, ii) demonstrated such arrhythmic activity in three out of nine cases (\~33%) during treatment with control solution (A) but in five out of six cases (\~83%) during treatment with flecainide (B). Furthermore, arrhythmic activity was observed in only one out of six such hearts (\~17%) during treatment with 1 μM quinidine (C) and in zero out of six hearts during exposure to 10 μM quinidine (D).

Graphical analyses of arrhythmogenic tendency {#Sec11}
---------------------------------------------

In an effort to explore the possible basis for these arrhythmic phenomena, subsequent experiments made systematic measurements of epicardial and endocardial action potential durations (at 90% repolarization, APD~90~s) during a dynamic pacing protocol \[[@CR17]\]. This consisted of cycles each comprising 100 stimuli, initially delivered at a BCL of 175 ms. BCL was then decremented in 50-ms steps with each subsequent cycle until a reproducible sequence of consistently shaped MAP waveforms was no longer obtained. Steady states were consistently reached within the first 50 responses, and therefore mean values of APD~90~ were obtained from the final 50 action potentials in each cycle. This approach provided data that could be used to evaluate over the full range of BCLs the relationship between arrhythmogenicity and two possible electrophysiological properties. Thus it was possible first to evaluate transmural repolarization gradients and secondly to evaluate slopes of restitution curves relating APD~90~ to the preceding DI, given by BCL minus APD~90~ \[[@CR17], [@CR25], [@CR28], [@CR43]\].

Relationships between epicardial and endocardial action potential durations are not consistently associated with either the presence or absence of arrhythmogenicity {#Sec12}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

Alterations in relationship between epicardial and endocardial APD~90~ determined at a single BCL has previously been associated with arrhythmogenicity in hearts obtained from our *Scn5a+/Δ* mice \[[@CR42]\]. The present study now extends this analysis from a single BCL to a range of BCLs and applies it to *Scn5a+/−* hearts for the first time, plotting endocardial APD~90~ on the abscissa and epicardial APD~90~ on the ordinate over the full range of BCLs investigated (triangles, Fig. [3](#Fig3){ref-type="fig"}). Such plots have previously been used to assess arrhythmogenicity in hypokalaemic WT murine hearts \[[@CR34]\] and provided possible criteria for arrhythmogenicity. The control plot obtained from WT hearts perfused with control solution (six hearts, Fig. [3](#Fig3){ref-type="fig"}a, A) gave a quadratic relationship between endocardial and epicardial APD~90~ (solid line), in agreement with previous work \[[@CR34]\]. Thus the curve *y* = *ax*^2^ + *bx* + *c*, where *a* = 0.0097 ± 0.0028, *b* = 1.46 ± 0.27 and *c* = −5.06 ± 6.34, gave a reduced *χ*^2^ of 0.49. Repeating the regression analysis this time fitting the line *y* = *mx* + *c* gave a reduced *χ*^2^ of 0.86, and permitted the derivation of an *F* statistic for the appropriate, *N* + 1 = 17 data points, given by $\documentclass[12pt]{minimal}
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\begin{document}$$ F_{\chi }  = N{\left( {\frac{{\chi _{2} ^{2}  - \chi _{3} ^{2} }} {{\chi _{3} ^{2} }}} \right)} $$\end{document}$ in which the subscripts on the right-hand side of the equation denote the number of parameters involved \[[@CR5]\]. This yielded a probability of exceeding *F* of \<0.05, suggesting that inclusion of the quadratic term was justified, again in full agreement with the previous study \[[@CR34]\]. Fig. 3Relationships between epicardial and endocardial action potential durations (at 90% repolarization, APD~90~s) obtained over a range of baseline cycle lengths. WT (**a**), *Scn5a+/Δ* (**b**) and *Scn5a+/−* (**c**) hearts were exposed to control solution (*A*) and to solutions containing 1 μM flecainide (*B*), 1 μM quinidine (*C*) and 10 μM quinidine (*D*) and stimulated at baseline cycle lengths of between 80 ms and 175 ms. *Broken lines* indicate reference curves constructed by least-squares fitting of the equation *y* = *ax*^2^ + *bx* + *c* to data points obtained from wild-type hearts treated with control solution

Data points obtained under the range of genetic and pharmacological conditions studied could then be compared with this reference curve (broken lines, Fig. [3](#Fig3){ref-type="fig"}) with the expectation that the departure of points to the left of this curve might be associated with arrhythmogenicity \[[@CR34]\]. However, data sets obtained before and after the pharmacological manoeuvres satisfied this expectation in WT but clearly failed to do so in the remaining genetically modified hearts.

First, treatment of WT hearts (Fig. [3](#Fig3){ref-type="fig"}a) with flecainide (five hearts, B), 1 μM quinidine (six hearts, C) and 10 μM quinidine (six hearts, D) all resulted in points falling to the left of the reference curve, *in parallel with* the occurrence of arrhythmic activity under these conditions (Fig. [2](#Fig2){ref-type="fig"}a, B, C and D). Secondly, data points obtained from *Scn5a+/Δ* hearts (Fig. [3](#Fig3){ref-type="fig"}b) treated with control solution (five hearts, A) again fell to the left of the reference curve *in contrast with* the low incidence of arrhythmic activity in this setting (Fig. [2](#Fig2){ref-type="fig"}b, A). This pattern was maintained when such hearts were exposed to flecainide (five hearts, Fig. [3](#Fig3){ref-type="fig"}b, B), once again in contrast with the low frequency which arrhythmic activity was observed under these conditions (Fig. [2](#Fig2){ref-type="fig"}b, B). Exposure to 1 μM quinidine (five hearts, Fig. [3](#Fig3){ref-type="fig"}b, C) and 10 μM quinidine (six hearts, D) again both resulted in points falling to the left of the control curve, this time in parallel with the high incidence of arrhythmic activity in these settings (Figs. [2](#Fig2){ref-type="fig"}b, C and [3](#Fig3){ref-type="fig"}b, D). Thirdly, data points obtained from *Scn5a+/−* hearts (Fig. [3](#Fig3){ref-type="fig"}c) treated with control solution (six hearts, A) consistently fell on the reference curve, in contrast with the occurrence of arrhythmic activity in this setting (Fig. [2](#Fig2){ref-type="fig"}c, A). Furthermore, treatment with flecainide (six hearts, Fig. [3](#Fig3){ref-type="fig"}c, B) failed to result in a left-shift of data points, in contrast with the large increase in the incidence of arrhythmic activity (Fig. [2](#Fig2){ref-type="fig"}c, B). In addition, points obtained during treatment with either 1 μM quinidine (five hearts, Fig. [3](#Fig3){ref-type="fig"}c, C) or 10 μM quinidine (seven hearts, D) again fell to the left of the reference curve, in contrast with the anti-arrhythmic effect of this agent demonstrated in Fig. [2](#Fig2){ref-type="fig"}c, C and D.

Alterations in the slopes of restitution curves correlate with the presence and absence of arrhythmic activity {#Sec13}
--------------------------------------------------------------------------------------------------------------

Restitution curves (data points, left ordinate) were then plotted using the APD~90~ (left ordinate) and DI data obtained during the dynamic pacing protocol from the epicardia (circles, Fig. [4](#Fig4){ref-type="fig"}) and endocardia (squares, Fig. [5](#Fig5){ref-type="fig"}) of WT (Figs. [4](#Fig4){ref-type="fig"}a, [5](#Fig5){ref-type="fig"}a), *Scn5a+/Δ* (Figs. [4](#Fig4){ref-type="fig"}b, [5](#Fig5){ref-type="fig"}b) and *Scn5a+/−* (Figs. [4](#Fig4){ref-type="fig"}c, [5](#Fig5){ref-type="fig"}c) hearts for the first time. Hearts were studied during treatment with control solution (A) and with solutions containing flecainide (B), 1 μM quinidine (C) or 10 μM quinidine (D). Under all conditions, epicardial and endocardial APD~90~ both decreased as DI decreased. Increases or decreases in the slopes of such relationships were in full agreement with the presence or absence of arrhythmic activity under all conditions studied. Fig. 4Epicardial restitution curves plotting action potential duration (at 90% repolarization, APD~90~) against preceding diastolic interval (DI). Data were obtained from the epicardia (*circles*) of WT (**a**), *Scn5a+/Δ* (**b**) and *Scn5a+/−* (**c**) hearts exposed to control solution (*A*) and to solutions containing 1 μM flecainide (*B*), 1 μM quinidine (*C*) and 10 μM quinidine (*D*). Curves are fitted with mono-exponential growth functions obtained by least squares fitting to the experimental values of APD~90~ and DI (*solid lines*, *left ordinates*). Gradients were obtained by differentiation of the fitted functions (*broken lines*, *right axes*). *Shaded boxes* indicate ranges of DI values at which such gradients exceed unityFig. 5Endocardial restitution curves plotting action potential duration (at 90% repolarization, APD~90~) against preceding diastolic interval (DI). Data were obtained from the endocardia (*squares*) of WT (**a**), *Scn5a+/Δ* (**b**) and *Scn5a+/−* (**c**) hearts exposed to control solution (*A*) and to solutions containing 1 μM flecainide (*B*), 1 μM quinidine (*C*) and 10 μM quinidine (*D*). Curves are fitted with mono-exponential growth functions obtained by least squares fitting to the experimental values of APD~90~ and DI (*solid lines*, *left ordinates*). Gradients were obtained by differentiation of the fitted functions (*broken lines*, *right axes*). *Shaded boxes* indicate ranges of DI values at which such gradients exceed unity

Restitution curves yield parameters predictive of arrhythmogenicity {#Sec14}
-------------------------------------------------------------------

To permit quantitative analysis, simple mono-exponential growth functions, as used previously \[[@CR28]\], were fitted to the experimental data. These took the form: $$\documentclass[12pt]{minimal}
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\begin{document}$$y = y_{0}  + A{\left( {1 - e^{{{ - x} \mathord{\left/ {\vphantom {{ - x} \tau }} \right. \kern-\nulldelimiterspace} \tau }} } \right)}$$\end{document}$$where *y* represents APD~90~, *x* represents DI, and *y*~*0*~, *A* and *τ* are constants obtained by least squares fitting to the experimental values of APD~90~ and DI in each case. These fitted parameters, along with corresponding reduced *χ*^2^ values, are shown in Tables [1](#Tab1){ref-type="table"} (epicardium) and [2](#Tab2){ref-type="table"} (endocardium). Curve fits performed on data sets obtained by separating successive odd- and even-numbered action potentials yielded statistically indistinguishable (*P* \> 0.05) parameters in all cases (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}) thus eliminating the possibility of error arising as a result of averaging. The corresponding gradients were then given by: $$\documentclass[12pt]{minimal}
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\begin{document}$$ \frac{{dy}} {{dx}} = \frac{A} {\tau } \cdot e^{{ - x/\tau }}  $$\end{document}$$and take their largest values at the shortest BCLs studied. Table 1Fit parameters for epicardial restitution curvesCondition*y*~0~ (ms)*A* (ms)*τ* (ms)*χ*^2^WT (6 hearts)1.6 ± 4.456.2 ± 2.458.4 ± 9.81.4WT + flecainide (5 hearts)−16.3 ± 9.4104.7 ± 7.182.8 ± 28.05.9WT + 1 μM quinidine (6 hearts)−38.3 ± 17.492.4 ± 14.745.1 ± 9.42.5WT + 10 μM quinidine (6 hearts)−863.0 ± 1,387.1981.6 ± 1,369.127.1 ± 15.9113.3*Scn5a+/Δ* (5 hearts)−19.6 ± 7.290.0 ± 4.453.1 ± 10.714.0*Scn5a+/Δ* + flecainide (5 hearts)−16.1 ± 6.582.2 ± 12.395.3 ± 42.13.5*Scn5a+/Δ* + 1 μM quinidine (5 hearts)−677.1 ± 306.1748.0 ± 304.715.2 ± 2.210.0*Scn5a+/−* (6 hearts)−674.8 ± 329.9729.4 ± 329.114.2 ± 2.18.4*Scn5a+/−* + flecainide (6 hearts)−56,359.8 ± 2,559.752,677.3 ± 2.27.8 ± 2.514.8*Scn5a+/−* + 1 μM quinidine (5 hearts)−118.3 ± 57.4202.5 ± 49.436.4 ± 10.516.7*Scn5a+/−* + 10 μM quinidine (7 hearts)−1.7 ± 44.7131.9 ± 62.3158.4 ± 262.210.8Results of least-squares fits to the function $\documentclass[12pt]{minimal}
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\begin{document}$$y = y_{0}  + A{\left( {1 - e^{{{ - x} \mathord{\left/ {\vphantom {{ - x} \tau }} \right. \kern-\nulldelimiterspace} \tau }} } \right)}$$\end{document}$ under the conditions indicatedTable 3Fit parameters for endocardial restitution curves separating successive odd- and even-numbered action potentialsConditionOddEven*y*~0~ (ms)*A* (ms)*τ* (ms)*χ*^2^*y*~0~ (ms)*A* (ms)*τ* (ms)*χ*^2^WT (6 hearts)13.4 ± 7.640.5 ± 12.950.3 ± 21.46.38.1 ± 11.258.3 ± 25.448.2 ± 32.34.6WT + flecainide (5 hearts)−14.7 ± 8.9105.2 ± 9.088.0 ± 31.35.8−44.6 ± 18.5117.4 ± 14.249.0 ± 9.91.5WT + 1 μM quinidine (6 hearts)−20.6 ± 9.975.8 ± 6.256.4 ± 13.23.8−34.2 ± 11.789.2 ± 9.345.9 ± 7.83.3WT + 10 μM quinidine (6 hearts)−1,391.7 ± 3,195.91,496.0 ± 3,182.021.1 ± 14.3117.9−393.1 ± 5.3.0532.8 ± 481.741.1 ± 27.6115.7*Scn5a+/Δ* (5 hearts)−23.9 ± 8.392.0 ± 5.347.8 ± 9.012.4−24.4 ± 8.692.6 ± 5.647.6 ± 8.911.8*Scn5a+/Δ* + flecainide (5 hearts)14.6 ± 6.377.1 ± 8.484.1 ± 32.23.4−33.2 ± 46.4110.1 ± 41.936.4 ± 13.12.0*Scn5a+/Δ* + 1 μM quinidine (5 hearts)−250.2 ± 12.8483.0 ± 24.518.8 ± 7.812.4−254.7 ± 321.2328.1 ± 318.320.0 ± 7.75.3*Scn5a+/−* (6 hearts)−850.4 ± 282.7904.2 ± 282.113.5 ± 1.34.3−913.3 ± 283.3968.6 ± 282.713.7 ± 1.23.7*Scn5a+/−* + flecainide (6 hearts)−1,473.8 ± 3,144.51,534.3 ± 2,141.214.7 ± 7.634.3−2,108.8 ± 4,489.92,171.3 ± 4,486.814.0 ± 6.735.0*Scn5a+/−* + 1 μM quinidine (5 hearts)−46.8 ± 51.2146.8 ± 21.359.5 ± 43.59.4−46.7 ± 50.6149.2 ± 20.261.0 ± 44.29.3*Scn5a+/−* + 10 μM quinidine (7 hearts)7.3 ± 34.2167.7 ± 264.8272.8 ± 78.310.82.8 ± 44.6143.1 ± 121.3192.2 ± 405.812.0Results of least-squares fits to the function $\documentclass[12pt]{minimal}
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\begin{document}$$y = y_{0}  + A{\left( {1 - e^{{{ - x} \mathord{\left/ {\vphantom {{ - x} \tau }} \right. \kern-\nulldelimiterspace} \tau }} } \right)}$$\end{document}$ under the conditions indicatedTable 4Fit parameters for endocardial restitution curves separating successive odd- and even-numbered action potentialsConditionOddEven*y*~0~ (ms)*A* (ms)*τ* (ms)*χ*^2^*y*~0~ (ms)*A* (ms)*τ* (ms)*χ*^2^WT (6 hearts)−17.4 ± 5.373.8 ± 2.867.3 ± 13.54.7−38.9 ± 15.491.6 ± 13.046.5 ± 8.51.8WT + flecainide (5 hearts)−49.2 ± 26.2113.8 ± 23.035.7 ± 8.27.6−367.3 ± 171.3426.9 ± 170.617.7 ± 2.41.3WT + 1 μM quinidine (6 hearts)−393.2 ± 368.6437.7 ± 368.614.9 ± 4.318.1−1,337.3 ± 1,206.41,384.5 ± 1,205.711.5 ± 2.514.7WT + 10 μM quinidine (6 hearts)−17.7 + −39.053.2 ± 35.042.6 ± 28.911.2−28.0 ± 62.766.6 ± 58.239.6 ± 29.717.3*Scn5a+/Δ* (5 hearts)−149.6 ± 131.4221.0 ± 128.626.4 ± 7.60.9−42.3 ± 10.5115.3 ± 8.240.8 ± 5.02.6*Scn5a+/Δ* + flecainide (5 hearts)−1,133.8 ± 784.21,201.4 ± 783.115.2 ± 2.62.0−2,164.0 ± 1,195.72,233.3 ± 1,195.013.6 ± 1.61.4*Scn5a+/Δ* + 1 μM quinidine (5 hearts)−2,720.4 ± 3,917.82,779.7 ± 3,917.210.4 ± 2.83.4−3,527.2 ± 4,674.783,603.0 ± 4,674.111.1 ± 2.73.9*Scn5a+/−* (6 hearts)−134.6 ± 28.9195.3 ± 28.022.8 ± 2.13.3−149.1 ± 33.5212.0 ± 32.622.9 ± 2.23.6*Scn5a+/−* + flecainide (6 hearts)−13.8 ± 29.266.2 ± 27.132.5 ± 11.11.8−55.4 ± 55.5108.6 ± 54.623.6 ± 5.91.2*Scn5a+/−* + 1 μM quinidine (5 hearts)−1,979.9 ± 1,709.02,051.5 ± 1,704.615.9 ± 2.813.4−108.4 ± 15,101.810,911.4 ± 15,098.311.8 ± 3.014.8*Scn5a+/−* + 10 μM quinidine (7 hearts)−332.1 ± 447.2431.4 ± 439.825.2 ± 12.7116.0−160.0 ± 289.5262.2 ± 281.920.1 ± 18.148.1Results of least-squares fits to the function $\documentclass[12pt]{minimal}
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Figures [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"} thus superimpose optimisations of Eq. [1](#Equ1){ref-type=""} to the data shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} (solid lines, left-hand ordinates). Furthermore, they show the corresponding gradients calculated using Eq. [2](#Equ2){ref-type=""} (broken lines, right-hand axes). Shaded regions where present indicate DIs less than the critical DI at which these gradients exceed unity: the existence of such a region is an established criterion for arrhythmogenesis \[[@CR25]\]. Critical DI was calculated as: $$\documentclass[12pt]{minimal}
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Figure [6](#Fig6){ref-type="fig"} proceeds to show these values of critical DI derived from the fitted values of *A* and *τ* for the epicardia (filled bars) and endocardia (open bars) under each of the above conditions. In contrast to the findings from the analysis of the relationships between epicardial and endocardial APD~90~s described above, the present analysis of epicardial and endocardial restitution properties together provided datasets *in complete agreement* with the observed incidences of arrhythmic activity. Fig. 6Critical diastolic intervals obtained from restitution curves. Critical diastolic intervals at which gradients equalled unity obtained from epicardial (*filled bars*) and endocardial (*open bars*) restitution curves shown in Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"} in WT (**a**), *Scn5a+/Δ* (**b**) and *Scn5a+/−* (**c**) hearts exposed to control solution (*A*) and to solutions containing 1 μM flecainide (*B*), 1 μM quinidine (*C*) and 10 μM quinidine (*D*). *Asterisks* indicate values that are significantly (*P* \< 0.05) larger than those recorded in WT hearts exposed to control solution

First, in WT hearts (Fig. [6](#Fig6){ref-type="fig"}a) exposed to control solution (A) the critical DI took a value of −63.63 ± 14.41 ms in the epicardium and −15.43 ± 4.97 ms in the endocardium. Treatment with flecainide (B) significantly (*P* \< 0.05) increased these values to 19.45 ± 9.39 ms in the epicardium and 58.75 ± 18.71 ms in the endocardium. This critical DI was attained in the endocardium (shaded region in Fig. [5](#Fig5){ref-type="fig"}a, B), in parallel with the increased incidence of arrhythmogenesis observed during the extrasystolic stimulation procedure under these conditions (Fig. [2](#Fig2){ref-type="fig"}, ii). Treatment with 1 μM quinidine (Fig. [6](#Fig6){ref-type="fig"}a, C) also significantly (*P* \< 0.05) increased the critical DI in both the epicardium and endocardium (32.30 ± 7.80 ms and 27.80 ± 14.53 ms respectively) in parallel with the observed arrhythmogenicity on extrasystolic stimulation under these conditions (Fig. [2](#Fig2){ref-type="fig"}, ii), although such values were not attained during the dynamic pacing protocol. Furthermore, treatment with 10 μM quinidine (Fig. [6](#Fig6){ref-type="fig"}a, D) again significantly (*P* \< 0.05) increased these values to 97.20 ± 57.90 ms in the epicardium and to 28.50 ± 34.52 ms in the endocardium. This DI was attained in the epicardium in parallel with the observed arrhythmogenicity during the extrasystolic stimulation procedure (Fig. [2](#Fig2){ref-type="fig"}, ii). Thus, increases in the critical DI are precisely *paralleled* with arrhythmogenicity in WT hearts treated with flecainide and quinidine.

Secondly, critical DIs obtained from *Scn5a+/Δ* hearts (Fig. [6](#Fig6){ref-type="fig"}b) were always significantly greater than those in WT controls (*P* \< 0.05 in all cases) in parallel with the increased incidence of arrhythmic activity observed during the extrasystolic stimulation procedure (Fig. [2](#Fig2){ref-type="fig"}, ii). Thus, in hearts treated with control solution (Fig. [6](#Fig6){ref-type="fig"}b, A) the critical DI increased to 28.04 ± 8.08 ms in the epicardium and 39.38 ± 10.28 ms in the endocardium: These values were attained in both the epicardium and endocardium in association with the increased incidence of arrhythmic activity on extrasystolic stimulation observed (Fig. [2](#Fig2){ref-type="fig"}, ii) and in full agreement with clinical expectations \[[@CR23]\]. Treatment with flecainide (Fig. [6](#Fig6){ref-type="fig"}b, B) decreased the epicardial value (−14.09 ± 9.05 ms, *P* \< 0.05 as compared to hearts treated with control solution) but did not significantly affect the endocardial value (21.41 ± 8.58 ms, *P* \> 0.05 as compared to hearts treated with control solution), having no effect on the observed incidence of arrhythmic activity on extrasystolic stimulation (Fig. [2](#Fig2){ref-type="fig"}, ii). However, treatment with 1 μM quinidine (Fig. [6](#Fig6){ref-type="fig"}b, C) significantly (*P* \< 0.05) increased both epicardial and endocardial values (59.09 ± 26.91 ms and 57.64 ± 16.68 ms, respectively) as compared to those obtained from such hearts treated with control solution, in association with the observed increases in the incidence of arrhythmic activity resulting from extrasystolic stimulation (Fig. [2](#Fig2){ref-type="fig"}, ii) and again in agreement with expectations from clinical work \[[@CR33]\]. It was not possible to obtain MAPs over a sufficiently wide range of BCLs to permit the construction of such curves in *Scn5a+/Δ* hearts treated with 10 μM quinidine.

Thirdly, critical DI values were also increased in *Scn5a+/−* hearts (Fig. [6](#Fig6){ref-type="fig"}c) in association with the increased incidence of arrhythmic activity observed. Thus, in hearts treated with control solution (A), the critical DIs were significantly (*P* \< 0.05) increased as compared to WT controls in both the epicardium and endocardium to 56.00 ± 27.79 ms and 52.59 ± 9.50 ms, respectively. These values were attained in both the epicardium and endocardium, fulfilling clinical expectations \[[@CR1]\]. Treatment with flecainide (B) did not significantly alter these values (68.14 ± 24.09 ms in the epicardium and 58.56 ± 14.75 ms in the endocardium). These were again attained in both epicardium and endocardium in association with the arrhythmic activity observed on extrasystolic stimulation (Fig. [2](#Fig2){ref-type="fig"}, ii). Furthermore, treatment with quinidine at a concentration of 1 μM (Fig. [6](#Fig6){ref-type="fig"}c, C) had no significant effect on critical DIs in either the epicardium or endocardium (62.45 ± 29.74 ms and 79.63 ± 39.31 ms, respectively). These values were again attained in both epicardium and endocardium. However, treatment with quinidine at 10 μM significantly decreased both epicardial and endocardial critical DIs, such that they became statistically indistinguishable from WT controls (29.01 ± 9.27 ms and −80 ± 3.58 ms, respectively). This was associated with the complete absence of arrhythmogenesis during the extrasystolic stimulation procedure (Fig. [2](#Fig2){ref-type="fig"}, ii).

Thus, while relationships between epicardial and endocardial action potential durations obtained over a range of cycle lengths are poorly correlated with arrhythmogenicity, restitution curves are, in general, predictive of arrhythmogenicity under the genetic and pharmacological conditions studied.

Discussion {#Sec15}
==========

The congenital LQT3 and the BrS constitute two important examples of genetic causes for ventricular arrhythmia and sudden cardiac death \[[@CR3]\]. These conditions result from similarly targeted mutations in the *SCN5a* gene coding for the cardiac Na^+^ channel: gain-of-function mutations are characteristic of LQT3, while loss-of-function mutations are characteristic of BrS \[[@CR1], [@CR23]\].

The present study began by using the MAP technique to verify that Langendorff-perfused murine hearts modelling LQT3 (*Scn5a+/Δ*) \[[@CR13]\] and BrS (*Scn5a+/−*) \[[@CR29]\] recapitulated features of the incidence of arrhythmic activity reported clinically. These results were in full agreement with previous physiological and pharmacological findings from our LQT3 \[[@CR39]\] and BrS \[[@CR38]\] models. Epicardial and endocardial MAP recordings were then used to evaluate the applicability of two established criteria in predicting arrhythmogenicity in these models over the full physiological range of heart rates (quantified as baseline cycle lengths, BCLs).

Transmural dispersion of repolarization was studied over a range of BCLs by comparing epicardial and endocardial action potential durations (at 90% repolarization, APD~90~s) in the two genetic models. Such an analysis had previously been demonstrated to reveal arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts \[[@CR34]\]. Furthermore, changes in this relationship investigated *at a single* BCL had previously been associated with arrhythmogenicity in our *Scn5a+/Δ* hearts \[[@CR42]\]. Plots of epicardial against endocardial APD~90~ in WT hearts treated with control solution gave reference relationships best fitted by a quadratic function, in full agreement with previous work \[[@CR34]\]. Treatment of such WT hearts with either quinidine or flecainide resulted in the data points falling to the left of the reference curves, reflecting increased transmural repolarization gradients, in association with increased incidences of arrhythmic activity and again in full agreement with a previous study \[[@CR34]\]. However, such plots failed to consistently predict the presence or absence of arrhythmogenicity in the *Scn5a+/Δ* and *Scn5a+/−* hearts. Such left-shifting of points was observed in *Scn5a+/Δ* hearts under *all* pharmacological conditions studied, despite the established anti-arrhythmic effect of flecainide in this setting. Furthermore, data points obtained from *Scn5a+/−* hearts treated with control solution fell *on* the reference curve despite the *increased* incidence of arrhythmic activity observed. Treatment with flecainide *failed* to result in a left-shift of points, despite its established *pro*-arrhythmic effect; treatment with quinidine *did* result in such a shift, despite its *anti*-arrhythmic effect.

These discrepancies prompted an investigation for alternative criteria for arrhythmogenicity. We therefore explored the applicability of a second approach involving restitution curves plotting APD~90~ against the preceding DI. Arrhythmic activity occurring in a range of settings has previously been associated with increases in the slopes of such curves to greater than unity \[[@CR14], [@CR17]--[@CR19], [@CR28], [@CR40]\]. Such an association has been demonstrated in a canine pharmacological model of the congenital long QT syndrome type 2 \[[@CR45]\] but has not previously been studied in *any* models of LQT3 or BrS in *any* species. Furthermore, decreases in the slopes of such curves have been associated with the effects of clinically important anti-arrhythmic drugs, including the class 1A agent procainamide in a canine model \[[@CR32]\]. However, such slopes have not been examined in relation to either quinidine or flecainide, nor have any such studies previously been attempted in murine models. This study accordingly proceeded to construct epicardial and endocardial restitution curves for the first time in a murine system and in relation to LQT3 or BrS in *any* species.

In contrast to the previous criterion, epicardial and endocardial restitution curves taken together yielded parameters in precise agreement with the presence or absence of arrhythmic phenomena demonstrated. In WT hearts, treatment with either quinidine or flecainide significantly increased the critical DI at which the slopes of the restitution curves exceeded unity, in full agreement with the increased incidences of arrhythmic activity observed. Not only did the *Scn5a+/Δ* and *Scn5a+/−* mutations result in significant increases in critical DI in association with increased rates of arrhythmic activity, but quinidine and flecainide exerted contrasting effects on this critical DI in agreement with clinical expectations in both cases. Thus, in *Scn5a+/Δ* hearts, treatment with quinidine increased critical DIs in association with its pro-arrhythmic effect. Furthermore, in *Scn5a+/−* hearts, treatment with quinidine decreased critical DIs in association with the decreased incidence of arrhythmic activity observed, while treatment with flecainide had the opposite effect. Thus class 1A agents may result in either increases (quinidine in WT and *Scn5a+/Δ* murine hearts) or decreases (quinidine in *Scn5a+/−* murine hearts and procainamide in canine hearts) \[[@CR32]\] in the critical DI: Such changes are in full agreement with effects on arrhythmogenicity in all cases.

Taken together, these results demonstrate that criteria considering effects on the slopes of restitution curves successfully account for arrhythmogenicity in murine models of arrhythmic syndromes resulting from mutations in the *Scn5a* Na^+^ channel, as well as for the effects of quinidine and flecainide on such arrhythmogenicity. These observations might form the basis for future clinical explorations of the utility of restitution curves obtained using the MAP technique \[[@CR28], [@CR40]\] in the assessment of arrhythmic propensity in hereditary arrhythmic syndromes. Such a robust means of assessing arrhythmogenicity might be particularly useful given the known variable expressivity of the arrhythmic phenotype in patients harbouring such mutations \[[@CR41]\].
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